Brief: Boehringer Ingelheim, Ose Immunotherapeutics: First Patient Dosed In Phase 1 Trial Evaluating BI 765063 Combined with Ezabenlimab

Ose Immunotherapeutics SA

30/09/2021 17:41

Sept 30 (Reuters) - OSE IMMUNOTHERAPEUTICS SA  OSE.PA :
    * BOEHRINGER INGELHEIM AND OSE IMMUNOTHERAPEUTICS ANNOUNCE
FIRST
PATIENT DOSED IN PHASE 1 EXPANSION TRIAL OF SIRPΑ ANTAGONIST
MONOCLONAL ANTIBODY BI 765063 IN COMBINATION WITH ANTI-PD-1
ANTIBODY EZABENLIMAB
    * DOSING OF FIRST PATIENT IN EXPANSION PHASE TRIGGERS A
MILESTONE
PAYMENT OF EUR 8 MILLION FROM BOEHRINGER INGELHEIM TO OSE
IMMUNOTHERAPEUTICS

Source text for Eikon:  ID:nBw81Nr01a 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))